The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells

Lorenzo Allegri, Federica Baldan, Sudeshna Roy, +4

Scientific Reports

Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics

Maria D’Agostino, Marialuisa Sponziello, Cinzia Puppin, +9

Journal of Molecular Endocrinology

MCM5 as a target of BET inhibitors in thyroid cancer cells

Catia Mio, Elisa Lavarone, Ketty Conzatti, +10

Endocrine Related Cancer

Bet InhibitorsEpigeneticsTumor BiologyAnaplastic Thyroid CarcinomaCell Regulation +16

Effects of nutraceuticals on anaplastic thyroid cancer cells

Lorenzo Allegri, Francesca Rosignolo, Catia Mio, +3

Journal of Cancer Research and Clinical Oncology

MedicineThyroid DiseasePathologyThyroid HormoneOncology +2

Anti-<i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft

Giovanni Enrico Lombardo, Valentina Maggisano, Marilena Celano, +12

Molecular Cancer Therapeutics

Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation

Cinzia Puppin, Cosimo Durante, Marialuisa Sponziello, +10

Endocrine

GeneticsMedullary Thyroid CarcinomasThyroid DiseasePathologyCancer Genomics +7

Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells

Valentina Maggisano, Marilena Celano, Giovanni Enrico Lombardo, +11

Molecular and Cellular Endocrinology

Tumor BiologyMedicineThyroid DiseasePathologyHtert Blocks Growth +6

Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line

Federica Baldan, Catia Mio, Lorenzo Allegri, +4

International Journal of Endocrinology

Anaplastic Thyroid CarcinomaOncologyOncogenic AgentMedicineThyroid Disease +11

Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells

Federica Baldan, Catia Mio, Elisa Lavarone, +4

Oncology Reports

Biological and molecular effects of bromodomain and extra‐terminal (<scp>BET</scp>) inhibitors <scp>JQ</scp>1, <scp>IBET</scp>‐151, and <scp>IBET</scp>‐762 in <scp>OSCC</scp> cells

Federica Baldan, Lorenzo Allegri, Miloš Lazarević, +4

Journal of Oral Pathology and Medicine